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Abstract
Purpose of Review Treatment of equine insect bite hypersensitivity (IBH) needs to be improved. Allergen-specific immunother-
apy (ASIT), the only curative treatment of allergy, currently has only a limited efficacy for treatment of IBH. This review
highlights the latest findings in prophylactic and therapeutic strategies.
Recent Findings Prophylactic vaccination against IBH using recombinant Culicoides allergen has been developed in unexposed
Icelandic horses and is ready to be tested. Therapeutic virus-like particle (VLP)–based vaccines targeting equine interleukin- (IL-)
5 or IL-31 improved clinical signs of IBH by induction of anti-cytokine antibodies thus reducing eosinophil counts or allergic
pruritus, respectively.
Summary First studies for development of ASIT using pure r-Culicoides allergens have yielded promising results and need now
to be tested in clinical studies for both prevention and treatment of IBH. Therapeutic vaccines inducing neutralizing antibodies
against IL-5 or IL-31 will be valuable future treatments for reduction of clinical signs of IBH.
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Introduction
Equine insect bite hypersensitivity (IBH), also known as
sweet itch, Queensland itch, summer eczema, or Kasen is
the most common allergic skin disease of horses [1] and is
clinically manifested as a chronic relapsing seasonal dermati-
tis [reviewed in 2]. IBH is initially presented as pruritic
dermatosis frequently affecting the mane and tail area follow-
ed by self-trauma leading to hair loss and excoriations, which
contribute to development of secondary bacterial infections
[2–4]. It is caused by bites of insects of the genus
Culicoides, known as biting midges [5, 6]. The prevalence
correlates with geographical distribution of the midges [7],
i.e. depends on environmental factors [8, 9] as well as on
genetic factors, such as breed, lineage or family [reviewed in
2]. IBH has been described worldwide, except in Iceland, and
affects approximately 10% of horses of all breeds [7].
While feeding, the midges inject a pool of various salivary
gland proteins leading to sensitization and allergy in
predisposed horses [10, 11]. Studies in humans have shown
that during the sensitization process, IL-25, IL-33, and thymic
stromal lymphopoietin (TSLP) are released from inflamed or
injured epithelial cells, inducing type 2 innate lymphoid cells
(ILC2) to produce IL-5 and IL-13 [12, 13]. Under the influ-
ence of these cytokines and TSLP, antigen-presenting cells
(APCs) direct the immune response towards Th2 with produc-
tion of IL-4 and IL-13. Subsequently, B cells undergo class
switch and produce allergen-specific IgE that binds to high
affinity FcεRI receptors on basophils and mast cells, leading
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to sensitization (Fig. 1A) [14, 15]. In sensitized, allergic indi-
viduals, re-exposure to the allergen causes cross-linking of
IgE bound to high-affinity FcεRI receptors on mast cells and
basophils and subsequent immediate release of effector cell
mediators. Vasoactive amines, lipid mediators, granule en-
zymes, and cytokines cause the clinical signs of immediate
hypersensitivity (Fig. 1B). Late-phase reaction occurs 2–4 h
after the exposure with a peak after 24 h. The release of in-
flammatory mediators by the activated mast cell causes infil-
tration of leukocytes, mostly Th2 cells and eosinophils at the
site of the allergic reaction (Fig. 1B) [14, 15].
Similarly to human allergy, various studies in horses have
shown an imbalance between a Th2 and T regulatory (Treg)/
Th1 immune response in IBH [16–19], with a relative increase
of the Th2 response. The involvement of IgE-mediated, type I
hypersensitivity reactions to Culicoides allergens with activa-
tion of mast cells, followed by a late-phase reaction character-
ized by infiltration of lymphocytes and eosinophils is well
established [reviewed in [7, 20, 21]. Few studies suggest a
possible involvement of delayed-type hypersensitivity
(DTH; type IV) in the pathogenesis of IBH [22]. Type IV
hypersensitivities can be further divided into types IVa, IVb,
IVc, and IVd based on predominant cell types. Type IVb of
DTH in drug hypersensitivity, is strongly associated with IL-5
producing Th2 cells and eosinophilia [23]. Eosinophils are
thus a common feature of both late-phase reaction of type I
hypersensitivities and type IV hypersensitivities. Moreover,
they seem to play a crucial role in IBH, as the allergic lesions
are often characterized by infiltration with eosinophils [7] and
eosinophilia is associated with severity of IBH [24••].
Furthermore, studies by Fettelschloss-Gabriel et al. indicate
an important role for IL-5 in the pathogenesis of IBH [24••,
25••]. IL-5 is a cytokine that displays multiple effects on eo-
sinophils and affects their differentiation, migration, activation
and survival. Once activated by IL-5, eosinophils release gran-
ule enzymes and effector molecules such as leukotrienes and
Fig. 1 Simplified scheme of type I hypersensitivity reaction as thought to
occur in insect bite hypersensitivity. Bold in the fig. legend indicates
mechanisms that have been demonstrated to be involved in IBH. (A)
Sensitization. (1) Culicoides midges bite horses, injecting saliva that
contains a variety of proteins. (2) Upon inflammation or damage, the
epithelium produces TSLP, IL-33, and IL-25. These cytokines act as
alarmins and activate group 2 innate lymphoid cells. (3) ILC2s secrete
IL-5 and IL-13. (4) APCs take up salivary gland proteins and are
modulated by the ILC2 cytokines. (5) APCs migrate to the draining
lymph node. (6) APCs present the allergen peptides on MHC class II to
naïve CD4+ T helper cells. (7) Naïve CD4+ T helper cells differentiate
into T helper type 2 cells (Th2). (8) Th2 cells produce IL-4 and IL-13 that
instruct the B cells to undergo class switching. (9) Upon class switching,
B cells produce allergen-specific IgE. (10) IgE binds to the high affinity
IgE receptor (FcεRI) onmast cells thus sensitizing the horse toCulicoides
allergens. (B) Re-exposure: immediate and late-phase reaction. (1) Upon
re-exposure to Culicoides allergens, (2) the allergens bind to the mast
cell–bound allergen-specific IgE antibodies, causing cross-linking
between the receptors. (3) Mast cells are thus activated and release
inflammatory mediators, such as histamine , leukotrienes ,
prostaglandins, and PAF, (4) leading to development of edema,
erythema, and itch, within minutes of allergen re-exposure. (5)
Activated mast cells also release chemokines and cytokines responsible
for the recruitment of effector cells to the allergy site. (6) These effector
cells are mainly eosinophils, Th2 cells, and basophils, causing the late-
phase reaction, which starts 2–4 h after exposure and reaches its peak at
24 h. (7) Th2 cells produce cytokines, in particular IL-5 that further
recruits eosinophils to the site of allergic inflammation
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major basic protein that in turn trigger degranulation of mast
cells and basophils, thus forming a vicious circle of allergic
inflammation.
Although IBH is the most common skin disease of horses,
the only efficient treatment available is, beside reduction of
exposure to Culicoides by stabling, use of blankets or repel-
lents, symptomatic therapy using glucocorticoids [7, 26].
Antihistamines seem to be of limited efficacy in the treatment
of IBH [27]. In this review we will highlight the most recent
developments in preventive options and treatments for the
equine IBH.
Allergen-Specific Immunotherapy
Allergen-specific immunotherapy (ASIT) is the only allergy
modifying treatment for type I hypersensitivities [28] and has
been shown to reduce progression of the disease as well as to
decrease the risk of development of new allergic conditions in
atopic patients [29]. ASIT has been used for therapy of human
allergies for over 100 years and was first applied by Noon
et al. who treated hay fever patients with pollen extract [30].
The mechanism underlying ASIT is thought to be a shift of the
immune response from Th2 towards a regulatory immune
response. In response to ASIT, IgG antibodies are produced,
in particular IgG4 that block the binding of allergen-specific
IgE antibodies to the allergens. Additionally, ASIT is associ-
ated with decreased production of IL-4 and IL-5, the signature
cytokines of Th2 CD4+ T cells [31], an increase of the
allergen-specific Treg with the production of regulatory cyto-
kines, IL-10 and TGF-β [32, 33], as well the induction of
allergen-specific Breg [34].
ASIT has proven to be relatively inexpensive, highly effec-
tive, and long-lasting when high-quality antigens are used
[35]. Allergen extracts have been used with a good outcome.
However, the success of therapy depends on the quality of the
extracts used as reviewed in Zhernov et al. On top of that,
standardization of allergen extracts is difficult. They can vary
greatly in the amount, potency and immunogenicity of indi-
vidual allergens and major allergens can be lacking [36]. As
IgE-mediated type I allergies are a global health problem af-
fecting around 30% of human population in industrialized
countries, it is vital to further develop ASIT with focus on
safety and clinical improvement using well-defined standard-
ized allergens [36]. The only way forward is by means of
molecular applications, and presently different strategies to
produce recombinant allergens are in development [35, 36]
with the aim to reduce their allergenicity but maintain immu-
nogenicity [37].
Another approach to control allergies is the use of preven-
tive immunotherapy, which can be applied in high-risk indi-
viduals before sensitization occurs, or in individuals with in-
creased allergen-specific IgE before development of clinical
signs [38]. To date, there are only few studies on preventive
immunotherapy. Campana et al. showed that vaccination of
non-allergic adults with recombinant hypoallergen derivatives
of the major birch pollen allergens, Bet v 1 in Alum decreased
the risk of developing birch allergy [39•].
Allergen-Specific Immunotherapy in Equine IBH
To our knowledge, three attempts to treat IBHwith ASIT have
been published [40–42]. All three have used whole body ex-
tract (WBE) of Culicoides midges. These crude WBE consist
of a mixture of hundreds of proteins and other substances,
whereby the salivary gland proteins, i.e. the allergens for
IBH, only represent a minute fraction of the extract.
Furthermore, the extracts were not derived from the most
abundant Culicoides species present in the environment of
horses. This might be important as van der Meide et al. have
shown that IBH-affected horses have higher IgE levels to
midges caught in the environment of the horses as compared
with laboratory-bred species [43].
In two placebo-controlled studies IBH-affected horses
treated with Culicoides whole body extract (WBE) showed
no significant improvement in clinical signs when compared
with the placebo-control group [40, 42]. However, in both
groups, clinical signs after vaccination improved when com-
pared with signs before vaccination, probably because of a
better insect control [42]. Anderson et al. obtained a signifi-
cant improvement of clinical signs in IBH-affected horses
treated with Culicoides WBE; however, a control group was
not included [41]. The low efficacy of ASITwith insect WBE
in early studies in humans [44, 45] as well as the controversial
non-conclusive results of these studies show the necessity of
using pure, well-defined allergens instead of crude WBE, ide-
ally by first defining the sensitization profile of each horses.
To achieve this goal, molecular approaches had to be applied
for identification and production of Culicoides salivary
allergens.
Culicoides Allergens in IBH
Over the last decade, extensive work has been put into iden-
tifying the causative allergens for IBH and producing them as
pure recombinant proteins. Allergens from the three
Culicoides species C. nubeculosus [46, 47], C. sonorensis
[48], and C. obsoletus [49, 50] have been identified and pro-
duced. All of them have been expressed in Escherichia coli,
some in insect cells and barley [51], and one inPichia pastoris
[52••] (Table 1).With a first available panel of allergens, Marti
et al. have set up a protein microarray for detection of the IgE
antibodies of IBH-affected horses [53•], which has now been
improved with the addition of further Culicoides allergens,
resulting in a total of 27 different Culicoides salivary proteins
[54••]. This approach is an efficient method for the elucidation
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of the most relevantCulicoides allergens. It will simplify map-
ping of the sensitization pattern of IBH-affected horses, which
in turn can serve as foundation for precision medicine–based
ASIT.
Preventive and Curative ASIT
Having access to pure Culicoides allergens opens the possi-
bility for development of both prophylactic and therapeutic
ASIT. Ideally, preventive immunotherapy should be carried
out prior to exposure to the allergens. Iceland is free of
Culicoides that feed on horses, and therefore horses in
Iceland do not suffer from IBH [55]. However, prevalence
of IBH in Icelandic horses exported to Culicoides endemic
area is high, as more than 50% of them get affected if not
protected from the midges [56, 57]. Since Icelandic horses
are only sensitized after the export, they offer a unique oppor-
tuni ty for development and study of prevent ive
immunotherapy.
For development of prophylactic vaccine, not only the
source of allergens and type of adjuvants have to be consid-
ered, but also the injection route may be of a great importance.
Studies by Senti et al. in human grass-pollen allergic patients
indicate that intralymphatic application of the allergens is
more efficient and does not have more side effects than the
subcutaneous route, commonly used in ASIT. Compliance to
ASIT is often low because of the long duration of treatment
and the many injections needed. The most important advan-
tage of the intralymphatic application compared with the con-
ventional treatment was that only 3 injections versus 54 were
required.
With the aim to develop a prophylactic ASIT against
equine IBH (Fig. 2), application route and adjuvants had first
to be evaluated. Two vaccination experiments using pure r-
Culicoides allergens were carried out in healthy Icelandic
horses not exposed to Culicoides. The aim was to determine
which immunization protocol would lead to the induction of a
Th1/Treg immune response with production of IgG-blocking
antibodies, an important feature of successful ASIT. In the first
study, horses were immunized 3 times at 4-week intervals,
receiving 10 μg of each allergen/injection either intradermally
or intralymphatically. This study showed that the adjuvant
IC31®, a TLR-9 agonist, was essential to induce a strong
antibody response. The induced antibodies, mainly IgG1 and
IgG4/7, were partly able to inhibit binding of IgE to the aller-
gens, i.e. blocking antibodies were induced. Importantly, no
allergen-specific IgE were induced by this prophylactic vac-
cination, indicating no risk of sensitization. The
intralymphatic route resulted in a slightly stronger antibody
response than the intradermal application [58••] and was used
in the second experiment. Unfortunately, IC31® was no more
available for use in horses; thus, in the second study, Alum
alone, an adjuvant often used in ASIT, was compared with a
combination of Alum and monophosphoryl lipid A (MPLA, a
TLR-4 agonist). Culicoides r-allergens mixed in Alum alone
and Alum/MPLA induced similar levels of allergen-specific
IgG1 and IgG4/7 antibodies with strong blocking capacity.
However, PBMC from horses vaccinated with Alum/MPLA,
but not those from horses vaccinated with Alum only, pro-
duced significantly more IFN-γ and IL-10 upon allergen-
specific in vitro re-stimulation as compared with unvaccinated
control horses [59••]. To summarize, intralymphatic injections
with small amounts of recombinant allergens in Alum/MPLA
resulted in a Th1/Treg immune response with induction of
high specific IgG antibodies levels, displaying a strong
blocking capacity. This indicates that such an immunization
protocol would be suitable for prophylactic ASIT. A challenge
experiment needs now to be performed to know whether this
type of prophylactic vaccination can protect Icelandic horses
against IBH after exposure to Culicoides.
As an alternative to subcutaneous immunotherapy (SCIT),
sublingual immunotherapy (SLIT) has also been shown to be
Table 1 Overview of published Culicoides allergens
Allergens C. nubeculosus kDa Allergens C. obsoletus kDa Allergens C. sonorensis kDa
Cul n 1 [46] Antigen 5–like protein 25 Cul o 1p [50] Kunitz protease inhibitor 23 Cul s 1 [48] Maltase 69
Cul n 2 [47] Hyaluronidase 47 Cul o 2p [50] D7-related salivary protein 18
Cul n 3 [47] Putative cystein endopeptidase 45 Cul o 1 [43] Maltase 67
Cul n 4 [47] Secreted salivary protein 18 Cul o 2 [43] Hyaluronidase 42
Cul n 5 [47] Secreted salivary protein 46 Cul o 3 [43] Antigen 5–like protein 28
Cul n 6 [47] Secreted salivary protein 17 Cul o 4 [43] Trypsin 27
Cul n 7 [47] Unknown salivary protein 21 Cul o 5 [43] Unknown salivary protein 18
Cul n 8 [47] Maltase 69 Cul o 6 [43] D7-related salivary protein 15
Cul n 9 [47] D7-related salivary protein 16 Cul o 7 [43] Secreted salivary protein 15
Cul n 10 [47] Secreted salivary protein 48
Cul n 11 [47] Trypsin 30
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effective in human patients [29] with the advantage that it can
be applied by the patients at home, reducing the number of
visits to the doctor [29].We are presently developing a version
of SLIT for horses, where a porridge of transgenic barley
expressing Culicoides allergens is brought in contact with
the oral mucosa using a special bit [52••]. This system has
the advantage that the barley grains are used directly, thus
bypassing protein purification, which is cumbersome and ex-
pensive. In a pilot study, four horses were treated 6 times with
this transgenic barley over a period of 20 weeks. After the
treatment, a weak IgG1 and IgG4/7 antibody response was
seen. Following one boost 8 months after the last treatment,
a stronger allergen-specific IgG1 and IgG4/7 antibody re-
sponse was achieved and the serum had some blocking activ-
ity. Allergen-specific antibodies could also be detected in the
saliva. This pilot experiment suggests that this approachmight
be a useful option for ASIT in horses. Transgenic barley ex-
pressing various Culicoides allergens is now being produced
with the aim to perform clinical trials in IBH-affected horses.
Therapeutic Vaccine Against IL-5
Eosinophils play a significant role in the pathogenesis of
IBH, making them important therapeutic targets. Besides
accumulating in IBH skin lesions, eosinophil counts were
also found to be enhanced in peripheral blood. In fact,
blood eosinophils were shown to correlate to IBH severity
score [24••]. In humans affected with hyper-eosinophilic
conditions, humanized monoclonal antibodies (mAb)
targeting the IL-5 or IL-5 receptor α have proven to be
safe and beneficial for the patients [60, 61]. This approach,
however, will probably not be available for equine patients
due to high production costs. A new approach has thus
been developed: In contrast to passive immunization ap-
proach with mAb, horses were actively immunized against
the eosinophilic master-molecule IL-5. Linkage of equine
IL-5 to VLPs of the cucumber mosaic virus (CuMV) gen-
erated polyclonal antibody responses against IL-5 in vac-
cinated horses [24••, 25••]. Since this approach is limited
by the horse’s own immune system, effective antibody titer
induction is ensured by the VLP design. Besides their
small size of 20–200 nm that enables free draining into
the lymphatic systems and mediates binding of native pro-
tein to B cell receptors, the VLP was optimized for effec-
tive stimulation of the innate and the adaptive immune
system. The surface of the VLPs is highly repetitive
allowing B cell receptor (BCR) cross-linking inducing po-
tent antibody responses in absence of T cells. This leads to
complement fixation via complement receptor 2 and sub-
sequent follicular dendritic cell activation driving T cell–
dependent differentiation of germinal center B cells into
Fig. 2 Simplified scheme of preventive allergen-specific immunotherapy
as described in this review. Immune reactions that have been
demonstrated in horses are indicated as bold in the fig. legend. (1) The
vaccine consisting of recombinant Culicoides allergens in adjuvants is
injected directly into the submandibular lymph node (A) or
subcutaneously (B) or intradermal. The advantage of the intralymphatic
injections being that the allergens are delivered directly at the site of the
immune response. (2) Antigen-presenting cells (APCs) take up the
allergens (3) and bring them to the draining lymph node (only B). (4) In
the lymph node, APCs present allergen peptides onMHC class II to naïve
CD4+ T helper cells. (5) Subsequently, naïve CD4+ T helper cells
differentiate into T helper type 1 (Th1) cells and/or T regulatory cells
(Tregs). (6) The Th1 cells produce IFN-γ, and instruct the B cells to
undergo class switching, (7) and start producing IgG and IgA
antibodies. (8) Additionally, Treg cells produce regulatory cytokines
IL-10 and TGFβ
Curr Derm Rep (2019) 8:303–312 307
class-switched affinity-matured long-lived plasma cells
[62]. In addition, the VLP contains non-coding E. coli
RNA activating innate immune receptors for pathogen-
associated molecular patterns (PAMPs) such as toll-like
receptor (TLR)-7 [63]. Finally, an integrated universal T
cell epitope of tetanus toxin (CuMVTT) suggests to boost
the immune response towards the vaccine in all tetanus-
vaccinated individuals [64]. Thus, the eIL-5-CuMVTT vac-
cine has been shown to induce effective antibody titers
against IL-5 that led to significantly reduced numbers of
eosinophils in blood of IBH-affected horses when compar-
ing to placebo treatment (Fig. 3) [25••]. The first treatment
year with two initial injections induced only short-lived
antibody titers, hence a mid-season booster injection was
required. However, once immunity was established by
three basic vaccination shots, a single annual booster in-
jection prior to IBH season was sufficient to maintain an-
tibody titer throughout the following IBH season. The
vaccine-induced anti-IL-5 antibody titers were shown to
be reversible, an important safety criterion [25••].
Moreover, studies in mouse models indicate that the en-
dogenous protein was not able to boost antibody titers in
absence of VLP-linkage, because the induced immune re-
sponse is dependent on the VLP-specific T cell help [65].
This represents an important autoimmunity safety criteri-
on. If confirmed in a clinical setting, this would represent
an advantage of the active vaccination over the passive
mAb approach, where anti-therapeutic antibodies can be
induced, limiting their use in affected patients [66].
Furthermore, the active immunization strategy described
here requires substantially less frequent injections and the
administered dose is significantly lower in the vaccine
compared with doses of therapeutic mAb. With regards to
clinical benefit, two placebo-controlled double-blind ran-
domized clinical trials with IBH-affected Icelandic horses
showed that the eIL-5-CuMVTT vaccine significantly re-
duced IBH lesion scores in line with decreased eosinophil
blood counts. The IBH lesion reduction was more pro-
nounced in the second treatment year due to more stable
antibody responses [24••, 25••].
Fig. 3 Simplified scheme of the mechanism of the therapeutic
vaccination against IBH with equine IL-5 virus–like particles (eIL5-
VLPs). (1) The horses are injected subcutaneously with the vaccine,
consisting of equine IL-5 linked to virus-like particles (eIL-5-VLPs). (2)
Within subcutaneous tissue, part of the vaccine will be taken up by
antigen-presenting cells (APCs) and (3) passive free drainage of vaccine
(allowed by particle size) and active APCmigration to the draining lymph
node occurs. (4) APCs including B cells present antigens either natively
or as epitopes onMHC class II to naïve CD4+ T helper cell. (5) Tcell help
provided for the MHC class II–presented foreign VLP antigens induce
class switching of VLP-specific B cells. (6) In parallel, eIL-5-specific B
cells receive bystander T help leading to class switching of eIL-5-specific
B cells (7) resulting in secretion of long-lived VLP- and IL-5-specific IgG
antibodies. (8) When the allergic horse is bitten by Culicoides, the
allergens are injected into the skin and (9) bind to mast cell–bound IgE,
leading to an immediate type allergic reaction. (10) Because endogenous
IL-5 is neutralized by the vaccine-induced antibodies, differentiation,
infiltration, and activation of eosinophils are inhibited and reduce
clinical sign of IBH
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Therapeutic Vaccine Against IL-31
A second vaccine using the same CuMVTTVLP backbone but
targeting equine IL-31 was generated by the same group. IL-
31 is mainly a Th2 cell–derived cytokine that directly interacts
with the nervous system via the IL-31 receptor expressed by
dorsal root ganglia cells in the skin and thus triggers allergic
pruritus [67, 68]. In IBH, it was shown that Culicoides aller-
gen stimulation of peripheral blood mononuclear cells
(PBMCs) produced significantly higher levels when derived
from IBH-affected horses as compared with healthy horses.
Moreover, IL-31 was shown to be exclusively expressed in
punch biopsies of IBH-affected skin lesions, whereas it was
not detected in non-lesional skin of the same horses or in skin
of healthy horses [69••]. A first placebo-controlled random-
ized double-blind study suggested clinical benefit by reduc-
tion of IBH lesion scores in the vaccine group over the placebo
group [69••]. Further studies including larger patient cohorts
and combining both IL-5 and IL-31 vaccines will elucidate
particular benefit of the vaccines for specific subgroups of
IBH-affected horses.
Other Treatment Options for IBH
Anecdotal reports indicated that treatment of horses with a
vaccine against dermatophytosis reduced clinical signs of
IBH, possibly by redirecting the immune response from Th2
towards Th1. A placebo-controlled study could, however, not
demonstrate a significant improvement of clinical signs after
three injections of Insol®-Dermatophyton [70]. Interestingly,
an increase in serum IFNλ, TNFα and IL-10 could only be
observed in the treated but not in the placebo group, indicating
the induction of a Th1/Treg immune response [70].
Additionally, topical treatments can also alleviate clinical
signs of IBH. A cream containing omega-3-fatty acids, hu-
mectants, and emollients has been shown to improve clinical
lesions of IBH, but did not influence the pruritic score [71].
JAK kinase inhibitors, as used for treatment of atopic der-
matitis in dogs [72], are not registered for treatment of horses.
Nevertheless, anecdotal reports indicate that the JAK kinase
inhibitor oclacitinib may have some effect for symptomatic
treatment of IBH.
Conclusions
Biologicals are increasingly used for treatment of allergy, and
the IL-5 and IL-31 therapeutic vaccines represent innovative
advances for symptomatic treatment of IBH. Further studies
are now needed to determine for which patient groups the
respective therapeutic vaccines are most suited and whether
their combination might further improve clinical response.
The availability of a large panel of pure recombinant
Culicoides allergens relevant for IBH open new options for
preventive and therapeutic ASIT. Suitable application routes
and adjuvants have been studies in horses not exposed to
Culicoides. A clinical trial for testing the efficacy of a preventive
ASIT needs to be performed. Finally, therapeutic ASITwith the
pure Culicoides allergens and the newly developed immuniza-
tion protocols can now be tested in IBH patients, ideally by
selecting the relevantCulicoides allergens for each IBH patients,
whereby the recently developed microarray represents an effi-
cient tool for selection of the required Culicoides allergens.
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